Antisoma Takes Refuge With Roche

Roche could easily have swallowed cash-poor Antisoma whole. But the Swiss group has instead bought rights to the UK biotech's entire clinical portfolio, hoping thereby to preserve Antisoma's creativity--rather like it has done with Genentech.